NextCure (NXTC) Shares Outstanding (2018 - 2026)
NextCure (NXTC) posted quarterly Shares Outstanding (Entity) of $5.2 million for Q1 2026, up 124.49% year-over-year from $2.3 million in Q1 2025, and up 84.32% quarter-over-quarter from $2.8 million in Q4 2025.
NextCure (NXTC) Shares Outstanding (2018 - 2026) Analysis & Trends
NextCure's Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 124.49% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (up 124.49% YoY), while the FY2025 annual figure was $2.8 million, up 21.79% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $5.2 million, up from $2.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $5.2 million in Q1 2026, with the low at $2.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $2.3 million (2024), against an average of $2.5 million.
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) grew 0.18% in 2023, then jumped 124.49% in 2026.
- NextCure's Shares Outstanding (Entity) stood at $2.3 million in 2022, then rose by 0.46% to $2.3 million in 2023, then climbed by 0.37% to $2.3 million in 2024, then rose by 21.79% to $2.8 million in 2025, then jumped by 84.32% to $5.2 million in 2026.
- Business Quant data shows NXTC's Shares Outstanding (Entity) at $5.2 million in Q1 2026, $2.8 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 5.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Mn |
| Mar 31, 2026 | 5.24 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.31 Mn |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 2.30 Mn |